Guggenheim Starts Nautilus Biotechnology (NAUT) at Buy

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ: NAUT) with a Buy rating and a price target of $6.00.

The analyst comments "NAUT's technology fills a market need for new proteome analysis tools. Existing approaches to protein analysis are limited in throughput and applications. Put another way, existing methods are only compatible with low sample volumes and/or require the researcher to know the protein they want to analyze, limiting the discovery applications of these technologies. NAUT's novel instrument addresses these shortcomings by enabling high-volume throughput (up to 10B individual proteins from 12 unique samples in a single run at maximum instrument capacity) and uses multi-affinity probes that do not require the user to know the proteins in the sample when designing the experiment."

For an analyst ratings summary and ratings history on Nautilus Biotechnology click here. For more ratings news on Nautilus Biotechnology click here.

Shares of Nautilus Biotechnology closed at $2.22 yesterday.

You May Also Be Interested In

• UBS Starts Elevra Lithium (ELV:AU) at Buy
• Shoals Technologies Group (SHLS) PT Raised to $12 at Jefferies
• Guggenheim Reiterates Buy Rating on Adagene Inc (ADAG)